Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. ElzEar Boulevard West, Laval, Canada

brunoq14 Sep. 12 at 12:22 PM

$BHC Durect's larsucosterol was granted Breakthrough status by the FDA.

0 · Reply

jonfvk Sep. 11 at 3:38 PM

$BHC should this news (and chart) pump this to 8 soon?

0 · Reply

LandonCapital Sep. 11 at 2:30 PM

$BHC https://landoncapital.net/healthy-decisions-bausch-health-nyse-bhc-completes-durect-acquisition-for-63-million/

0 · Reply

Bobberty Sep. 11 at 12:46 PM

$BHC may get back in if it dips some more. No clue if she'll survive or not but if she can then it's got potential to make some huge money. I'll gamble a couple thousand $ on that.

1 · Reply

Thestocktraderhubzee Sep. 11 at 12:42 PM

$BHC Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

0 · Reply

TwongStocks Sep. 11 at 12:41 PM

$BHC Completes Acquisition of $DRRX, Expanding Late-stage Liver Disease Portfolio https://www.prnewswire.com/news-releases/bausch-health-completes-acquisition-of-durect-corporation-expanding-late-stage-liver-disease-portfolio-302553904.html DRRX shares were halted last night by NASDAQ. Shareholders will receive $1.75 and a CVR per share. If you owned 1000 DRRX, you will get $1750 and 1000 CVRs in your account. May take a few days for brokers to process the transaction into your accounts.

0 · Reply

MyFriendsCallMeMoe Sep. 10 at 2:37 PM

$BHC Anyone care to give their bull case?

3 · Reply

G101SPM Sep. 9 at 3:06 PM

G101SPM 8/15/2025, 8:17:01 AM $BHC $8.23 bid. DAC $7.40 (8.14.25). EXIT $12.00.

0 · Reply

G101SPM Sep. 9 at 3:04 PM

G101SPM 8/14/2025, 7:59:56 AM $BHC $7.40 ask. BUY/REVISIT carries SPM 87.24 tag to $12.00 in midterm

0 · Reply

OX50 Sep. 6 at 6:30 PM

$BHC Fidelity has BHC rating bullish 8.4 out of 10 with two known analyst LSEG and Trading Central covered the stock as a buy on Sep. 4th nd Sep. 5th.

0 · Reply

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Sep 11, 2025, 8:35 AM EDT - 4 days ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 7:00 AM EDT - 4 days ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 9, 2025, 7:00 AM EDT - 6 days ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 5, 2025, 8:02 AM EDT - 10 days ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Aug 26, 2025, 8:00 AM EDT - 20 days ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

Aug 21, 2025, 8:02 AM EDT - 25 days ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Aug 18, 2025, 5:48 PM EDT - 27 days ago

Bausch + Lomb board members resign after Icahn agreement ends

Aug 15, 2025, 2:30 PM EDT - 4 weeks ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Aug 12, 2025, 1:02 PM EDT - 4 weeks ago

Why Bausch Health Stock Surged By Nearly 20%

Aug 7, 2025, 8:00 AM EDT - 5 weeks ago

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Jul 30, 2025, 11:30 PM EDT - 6 weeks ago

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 6 weeks ago

Bausch Health Announces Second Quarter 2025 Results

Jul 29, 2025, 2:21 PM EDT - 6 weeks ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

DRRX

Jul 29, 2025, 7:00 AM EDT - 6 weeks ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Jul 29, 2025, 7:00 AM EDT - 6 weeks ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 28, 2025, 9:10 AM EDT - 7 weeks ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 24, 2025, 8:02 AM EDT - 7 weeks ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Jul 10, 2025, 5:00 PM EDT - 2 months ago

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Jul 10, 2025, 4:15 PM EDT - 2 months ago

Bausch Health Appoints New Chief Accounting Officer

Jul 9, 2025, 8:00 AM EDT - 2 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Jul 7, 2025, 8:00 AM EDT - 2 months ago

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Jul 2, 2025, 7:00 AM EDT - 2 months ago

Bausch Health to Announce Second Quarter 2025 Results on July 30

Jun 26, 2025, 4:30 PM EDT - 2 months ago

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Jun 22, 2025, 5:00 AM EDT - 3 months ago

A Billionaire Trump Supporter Is Buying These Two Stocks

PPTA

Jun 18, 2025, 11:01 AM EDT - 3 months ago

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

Jun 16, 2025, 4:04 AM EDT - 3 months ago

Repricing Potential Driven By Deleveraging

Jun 4, 2025, 6:59 AM EDT - 3 months ago

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

May 21, 2025, 9:45 AM EDT - 4 months ago

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma

May 21, 2025, 6:59 AM EDT - 4 months ago

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

May 14, 2025, 4:15 PM EDT - 4 months ago

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

May 14, 2025, 6:59 AM EDT - 4 months ago

Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

May 7, 2025, 7:00 AM EDT - 4 months ago

Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

May 6, 2025, 8:00 AM EDT - 4 months ago

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Apr 30, 2025, 7:51 PM EDT - 4 months ago

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 4 months ago

Bausch Health Announces First Quarter 2025 Results

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Apr 22, 2025, 9:33 AM EDT - 5 months ago

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Apr 22, 2025, 8:54 AM EDT - 5 months ago

Bausch Health says Carl Icahn has exposure to about 34% of company's shares

Apr 22, 2025, 7:25 AM EDT - 5 months ago

Bausch Health Announces Filing of Supplement to Proxy Statement

Apr 21, 2025, 7:00 AM EDT - 5 months ago

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Apr 17, 2025, 3:40 PM EDT - 5 months ago

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Apr 14, 2025, 4:30 PM EDT - 5 months ago

Bausch Health Announces Adoption of Shareholder Rights Plan

Apr 10, 2025, 4:15 PM EDT - 5 months ago

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Apr 9, 2025, 8:00 AM EDT - 5 months ago

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

Apr 5, 2025, 3:00 AM EDT - 5 months ago

Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity

Apr 2, 2025, 8:00 AM EDT - 5 months ago

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

Mar 27, 2025, 8:44 AM EDT - 6 months ago

Bausch + Lomb recalls some of its implantable eye lenses

Mar 27, 2025, 7:30 AM EDT - 6 months ago

Bausch + Lomb Recalls EnVista Intraocular Lenses

Mar 27, 2025, 7:00 AM EDT - 6 months ago

Bausch Health to Announce First Quarter Results on April 30

brunoq14 Sep. 12 at 12:22 PM

$BHC Durect's larsucosterol was granted Breakthrough status by the FDA.

0 · Reply

jonfvk Sep. 11 at 3:38 PM

$BHC should this news (and chart) pump this to 8 soon?

0 · Reply

LandonCapital Sep. 11 at 2:30 PM

$BHC https://landoncapital.net/healthy-decisions-bausch-health-nyse-bhc-completes-durect-acquisition-for-63-million/

0 · Reply

Bobberty Sep. 11 at 12:46 PM

$BHC may get back in if it dips some more. No clue if she'll survive or not but if she can then it's got potential to make some huge money. I'll gamble a couple thousand $ on that.

1 · Reply

Thestocktraderhubzee Sep. 11 at 12:42 PM

$BHC Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

0 · Reply

TwongStocks Sep. 11 at 12:41 PM

0 · Reply

MyFriendsCallMeMoe Sep. 10 at 2:37 PM

$BHC Anyone care to give their bull case?

3 · Reply

G101SPM Sep. 9 at 3:06 PM

G101SPM 8/15/2025, 8:17:01 AM $BHC $8.23 bid. DAC $7.40 (8.14.25). EXIT $12.00.

0 · Reply

G101SPM Sep. 9 at 3:04 PM

G101SPM 8/14/2025, 7:59:56 AM $BHC $7.40 ask. BUY/REVISIT carries SPM 87.24 tag to $12.00 in midterm

0 · Reply

OX50 Sep. 6 at 6:30 PM

$BHC Fidelity has BHC rating bullish 8.4 out of 10 with two known analyst LSEG and Trading Central covered the stock as a buy on Sep. 4th nd Sep. 5th.

0 · Reply

TheArrowUp Sep. 5 at 7:49 PM

$BHC almost as if our two biggest owners are walking price down piddling shares with each other back and forth?

0 · Reply

algomezus Sep. 5 at 12:23 PM

$BHC solita is kicking butt. How in the world is this worth so little?.

2 · Reply

FU2 Sep. 4 at 11:16 PM

$BHC Friday 6.90's low closing in low 7's. Clock work people. Criminal

0 · Reply

thechadrandy Sep. 4 at 10:47 PM

$BHC

0 · Reply

FU2 Sep. 3 at 3:19 PM

$BHC its all about options here. Not share holder value..fricken joke

0 · Reply

FU2 Sep. 3 at 3:17 PM

$BHC hate to be that guy, but welcome to our newest bag holders. Just when you think all looks good, nope. Let the games continue. 5 million shares yesturday to this. Criminal..stay away

0 · Reply

BW69 Sep. 3 at 2:24 PM

$BHC $BLCO 88% not 80%!

0 · Reply

GDS_investing Sep. 2 at 4:54 PM

$BHC looking good on red day LONG

0 · Reply

Neildc Sep. 2 at 4:16 PM

$BHC Finally the trading is this is looking bullish Fundamentals have been surprisingly decent The turnover in the ownership is resolved The shares are a double

0 · Reply

ebu Sep. 2 at 3:21 PM

$BHC Just a bizarre stock. Always going in the wrong direction of the stock market 😒

0 · Reply

sogenerous Sep. 2 at 2:07 PM

$BHC nice rel strength today - maybe its nothing

2 · Reply

StockConsultant Aug. 31 at 10:38 PM

$BHC Bausch Health stock, good rally off of the 6.96 triple support area at https://stockconsultant.com/?BHC

0 · Reply

Market Cap	2.69B
Revenue (ttm)	9.63B
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	1.93
Forward PE	2.03
Profit Margin	-0.48%
Debt to Equity Ratio	147.88

Volume	984,572
Avg Vol	2,804,004
Day's Range	N/A - N/A
Shares Out	370.35M
Stochastic %K	24%
Beta	0.48
Analysts	Hold
Price Target	$7.08